Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.77 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 7/20 | 0.53 |
| ▸ | ATP4A | P20648 | 1/20 | 0.52 |
| ▸ | ATP4B | P51164 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21017825 | 0.94 | ACHE (0.67) | ACHECHEK2BRAFATP4AATP4B | |
| SCHEMBL21018444 | 0.93 | ACHE (0.67) | ACHECHEK2BRAFATP4AATP4B | |
| SCHEMBL21017228 | 0.92 | ACHE (0.66) | ACHECHEK2ATP4AATP4BCHRNB4 | |
| SCHEMBL21018108 | 0.92 | ACHE (0.69) | ACHECHEK2BRAFATP4AATP4B | |
| SCHEMBL21017614 | 0.91 | ACHE (0.65) | ACHECHEK2ATP4AATP4BHDAC6 | |
| SCHEMBL21018408 | 0.88 | CHEK2 (0.61) | ACHECHEK2BRAFATP4AATP4B | |
| SCHEMBL21017221 | 0.88 | ACHE (0.63) | ACHECHEK2ADORA2AADORA1HDAC6 | |
| SCHEMBL21017841 | 0.88 | ACHE (0.60) | ACHECHEK2BRAFATP4AATP4B | |
| SCHEMBL21017830 | 0.87 | ACHE (0.73) | ACHECHEK2ATP4AATP4BADORA3 | |
| SCHEMBL21017655 | 0.87 | ACHE (0.65) | ACHECHEK2ATP4AATP4BCHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | ACHE 2382/4885CHEK2 1163/4885BRAF 4381/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | ACHE 2382/4885CHEK2 1163/4885BRAF 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.